Co-Authors
This is a "connection" page, showing publications co-authored by SOUMEN KHATUA and DAVID SANGHYUN HONG.
Connection Strength
0.041
-
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2.
Score: 0.041
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.